Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-β1 in the MRL/lpr lupus mouse model

Lupus

Volumn 17, Issue 9, 2008, Pages 822-831

  Kaplan, Johanne M ^a   Woodworth, L ^a   Smith, K ^a   Coco, J ^a   Vitsky, A ^a   McPherson, J M ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Anti thymocyte globulin; Lupus; MRL lpr; TGF ; Treg or regulatory T cells

Indexed keywords

ALBUMIN; AUTOANTIBODY; CYCLOPHOSPHAMIDE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; ANTINUCLEAR ANTIBODY; IMMUNOLOGIC FACTOR; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LYMPHOCYTE ANTIBODY;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GLOMERULAR DYSFUNCTION; HISTOPATHOLOGY; IN VITRO STUDY; LYMPHOCYTE DEPLETION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEINURIA; RABBIT; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; URINARY CAST; ANIMAL; BLOOD; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; GLOMERULUS; LONGEVITY; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTILYMPHOCYTE SERUM; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOLOGIC FACTORS; KIDNEY GLOMERULUS; LATENT TGF-BETA BINDING PROTEINS; LONGEVITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; PROTEINURIA; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 58949100003     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308091635     Document Type: Article

References (32)

1. Miyara M Amoura Z Parizot C. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175: 8392-8400.
2. + T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 2004; 59: 198-202.
3. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579-2588.
4. Robson MG Walport MJ. Pathogenesis of systemic lupus erythematosus (SLE). Clin Exp Allergy 2001; 31: 678-685.
5. Schlomchik MJ Craft JE Mamula MJ. From T to B and back again: Positive feedback in systemic autoimmune disease. Nature Rev Immunol 2001; 1: 147-153.
6. Stohl W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic disease. Endocr Metab Immune Disord Drug Targets 2006; 6: 351-358.
7. Gillis JZ Dall'era M Gross A Yazdany J Davis J. Six refractory lupus patients treated with rituximab: A case series. Arhtritis Rheum 2007; 57: 538-542.
8. Tanaka Y Yamamoto K Takeuchi T. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17: 191-197.
9. Brennan DC Flavin K Lowell JA. A randomized, double-blinded comparison for thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
10. + regulatory T cells. Am Soc Nephrol 2006; 17: 2844-2853.
11. + regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006; 176: 4125-4132.
12. + regulatory T cells from human peripheral blood. J Immunol 2001;166: 7282-7289.
13. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886.
14. + T cells. J Immunol 2004; 173: 6526-6531.
15. Rao PE Petrone AL Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. J Immunol 2005; 174: 1446-1455.
16. Selvaraj RK Geiger TL. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-β. J Immunol 2007; 178: 7667-7677.
17. + regulatory T cells and for expansion of these cells. J Immunol 2007; 178: 2018-2027.
18. Calabresi PA Fields NS Maloni HW. Phase I trial of transforming growth factor β2 in chronic progressive MS. Neurology 1998; 51: 289-292.
19. Munger JS Harpel JG Gleizes PE. Latent transforming growth factor-β: Structural features and mechanisms of activation. Kidney Int. 1997; 51: 1376-1382.
20. Wang J Zhu Z Nolfo R Elisa J. Dexamethasone regulation of lung epithelial cell and fibroblast interleukin-11 production. Am J Physiol 1999; 276: L175-L185.
21. Chan OTM Hannum LG Haberman AM. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189: 1639-1647.
22. Clynes R Dumitru C Ravetch JV. Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. Science 1998; 279: 1052-1054.
23. Balomenos D Rumold R Theofilopoulos AN. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 1998; 101: 364-371.
24. Kulkarni O Pawar RD Purschke W. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18: 2350-2358.
25. Rodriguez W Mold C Marnell LL. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006; 54: 325-335.
26. + regulatory T cells. J Exp Med 2005; 7: 1061-1067.
27. Harada M Makino S. Suppression of overt diabetes in NOD mice by anti-thymocyte serum or anti-Thy 1.2 antibody. Exp Anim 1986; 35: 501-504.
28. Maki T Ichikawa T Blanco R Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci 1992; 89: 3434-3438.
29. Ogawa N List JF Habener JF Maki T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 2004; 53: 1700-1705.
30. Yang M-H Suen J-L Li S-L Chiang B-L;. Identification of T-cell epitopes on U1A protein in MRL/lpr mice: Double-negative T cells are the major responsive cells. Immunology 2005; 115: 279-286.
31. Ahuja A Shupe J Dunn R. Depletion of B cells in murine lupus: Efficacy and resistance. J Immunol 2007; 179: 3351-3361.
32. Wahl SM Wen J Moutsopoulos N. TGF-β: A mobile purveyor of immune privilege. Immunol Rev 2006; 213: 213-227.